OPKO Health, Inc. Inventory, Finished Goods, Gross
OPKO Health, Inc. (OPK) had Inventory, Finished Goods, Gross of $40.01 million as of 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Balance Sheet › Assets › Assets, Current › Inventory, Net
us-gaap:InventoryFinishedGoods · last filed 2026-08-28
- 2026-06-30: Inventory, Finished Goods, Gross $40.01M.
- 2026-03-31: Inventory, Finished Goods, Gross $44.09M.
- 2025-12-31: Inventory, Finished Goods, Gross $43.99M.
- 2025-09-30: Inventory, Finished Goods, Gross $42.26M.
| Period end | Inventory, Finished Goods, Gross |
|---|---|
| 2026-06-30 | $40.01M 10-Q/A · filed 2026-08-28 |
| 2026-03-31 | $44.09M 10-Q/A · filed 2026-08-28 |
| 2025-12-31 | $43.99M 10-Q/A · filed 2026-08-28 |
| 2025-09-30 | $42.26M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $42.20M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $39.88M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $32.31M 10-K · filed 2026-02-26 |
| 2024-09-30 | $34.21M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $34.48M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $34.01M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $35.58M 10-K · filed 2025-03-03 |
| 2023-09-30 | $35.05M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $36.46M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $39.26M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $37.14M 10-K · filed 2024-03-01 |
| 2022-09-30 | $37.19M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $42.32M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $46.59M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $44.11M 10-K · filed 2023-02-27 |
| 2021-09-30 | $40.64M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $38.87M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $39.29M 10-Q · filed 2021-04-28 |
| 2020-12-31 | $36.83M 10-K · filed 2022-03-01 |
| 2020-09-30 | $30.27M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $24.26M 10-Q · filed 2020-07-31 |
| 2020-03-31 | $23.73M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $25.14M 10-K · filed 2021-02-18 |
| 2019-09-30 | $22.14M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $21.48M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $18.89M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $15.26M 10-K · filed 2020-03-02 |
| 2018-09-30 | $14.93M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $16.78M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $22.14M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $21.01M 10-K · filed 2019-03-01 |
| 2017-09-30 | $22.88M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $21.82M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $19.73M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $16.14M 8-K · filed 2019-01-29 |
| 2016-09-30 | $14.03M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $13.94M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $14.79M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $13.40M 10-K · filed 2017-03-01 |
| 2015-09-30 | $13.85M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $13.83M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $14.35M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $12.12M 10-K · filed 2016-02-29 |
| 2014-09-30 | $11.36M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $12.46M 10-Q · filed 2014-08-11 |
| 2014-03-31 | $12.88M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $13.37M 10-K · filed 2015-02-27 |
| 2013-09-30 | $14.78M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $15.17M 10-Q · filed 2013-08-09 |
| 2013-03-31 | $19.18M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $17.96M 10-K · filed 2014-03-03 |
| 2012-09-30 | $17.75M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $14.69M 10-Q · filed 2012-08-09 |
| 2011-12-31 | $11.10M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |